In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Allscripts Healthcare Solutions MDRX with a Buy rating and $17.00 price target.
In the report, Sterne Agee noted, “We believe Allscripts is in the 3rd inning of a long-term turnaround. The company has reshuffled executive leadership, rightsized-(ing) its organization, launched major product upgrades, and scuttled legacy ambulatory products. With a void only filled by two major players within the integrated acute-ambulatory clinical marketplace, we think Allscripts is retooling its organization to be a formidable third player. Re-initiating with Buy rating and $17 price target.”
Allscripts Healthcare Solutions closed on Tuesday at $13.75.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in